The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Parkside Psychiatric Hospital in Tulsa has an on-site Spravato outpatient clinic that sees over 20 patients per week. According to Parkside, these patients are seen at least twice a week for the ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD ...

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

Now, the Food and Drug Administration (FDA) has expanded approval for Johnson & Johnson's nasal spray, Spravato, to be used as a standalone treatment for people with severe depression who haven't ...

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

In this study, participants with TRD were randomly assigned to receive intranasal Spravato monotherapy at either 56mg or 84mg, administered twice weekly, or placebo nasal spray for 4 weeks.

doses of Spravato achieved MDD remission with an MADRS total score of less than or equal to 12, and 18.3% of those on 56 mg does achieved remission, compared to 7.6% of participants taking the ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday. MDD ...